Sarizotan

Sarizotan

Systematic (IUPAC) name
1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-([5-(4-fluorophenyl)pyridin-3-yl]methyl)methanamine
Clinical data
Pregnancy category	N/A
Legal status	Discontinued
Routes of administration	Oral
Identifiers
CAS Number	177975-08-5
ATC code	none
PubChem	CID: 6918388
ChemSpider	2319847
UNII	467LU0UCUW Y
Chemical data
Formula	C22H21FN2O
Molecular mass	348.413 g/mol
SMILES C1CC2=CC=CC=C2O[C@H]1CNCC3=CN=CC(=C3)C4=CC=C(C=C4)F

Sarizotan (EMD-128,130) is a selective 5-HT_1A receptor agonist and D₂ receptor antagonist, which has antipsychotic effects, and has also shown efficacy in reducing dyskinesias resulting from long-term anti-Parkinsonian treatment with levodopa.

In June 2006, the developer Merck KGaA announced that the development of sarizotan was discontinued, after two sarizotan Phase III studies (PADDY I, PADDY II) failed to meet the primary efficacy endpoint and neither the Phase II findings nor the results from preclinical studies could be confirmed. No statistically significant difference of the primary target variable between sarizotan and placebo could be demonstrated.

See also

• Osemozotan
• Piclozotan
• Robalzotan